In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report), ...

Health-care companies rose as a reported U.S. death from bird flu stoked fears of a new pandemic, boosting shares of vaccine makers.

MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.

MAIA Biotechnology (MAIA) announced that it has entered into a clinical supply agreement with BeiGene (BGNE) to assess the efficacy of THIO, ...

MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications ...